Business Daily from THE HINDU group of publications
Tuesday, Sep 19, 2006

Cross Currency

Group Sites

Industry & Economy - Health
`GSK drug may cut risk of developing diabetes'

Our Bureau

New Delhi , Sept. 18

The use of rosiglitazone medicine may reduce the risk of developing diabetes. In a result of a clinical trial discussed on Monday, the use of the medicine reduced the risk of developing diabetes by 62 per cent compared to a placebo among 5,269 people at risk of developing the disease.

This reduction was in addition to counselling on healthy eating and exercise. The DREAM (Diabetes Reduction Assessment with ramipril and rosiglitazone Medication) trial, conducted by Population Health Research Institute at McMaster University of Canada, evaluated the likelihood of progression to diabetes from pre-diabetes stage over a three-year period.

Rosiglitazone is manufactured by GlaxoSmithKline (GSK) that is also one of the companies that funded the trials. GSK markets the medicine by the `Windia' brand in India.

Six centres from India participated in the trial. Although the initial results of the trial favour the use of rosiglitazone for the treatment of the disease, some more results are awaited from it.

Dr V. Mohan, Chairman, Dr Mohan's Diabetes Specialities Centre, one of the participating clinics, said, "We do not know as yet if the medicine actually treats the disease or only masks it. The subjects will now be kept away from medication for three months under the ongoing study to find this out."

Results of this trial were presented last Friday at the 42nd Annual Meeting of the European Association for the study of diabetes and published in the Lancet journal.

More Stories on : Health | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Economy to grow 8-9 pc, says RBI Governor

Health expenditure in India
Special problems, special solutions
Degremont estimates € 100 m by 2010 from Indian operations
Forests will be protected, says Kerala Minister
Economic mission to Italy
Union Bank in pact with DGFT
Malaysia invites investments in pharma, chemicals
Israel keen to set up mutual R&D fund with India
`Cut health insurance premium rate'
`GSK drug may cut risk of developing diabetes'
Eli Lilly launches cancer drug
Buddhadeb urges uniform land-use policy for SEZs
Infrastructure Financing — Accountability is not axiomatic
Grand sight
Indian crude basket drops below $60
GIC eyes expansion in reinsuring energy risks
NF Rly not to be hit by Numaligarh refinery pipeline
Meeting on award of CBM remains inconclusive
Withdraw strike, Deora appeals to petro-dealers
Petrol-pump dealers strike: Mumbaikars only partially hit
AP plans SEZ for pharma formulations
Jupiter Capital to invest Rs 100 cr
Hosiery town goes still
After clear glass, Saint-Gobain moves up the value chain
`Monopolistic trends in press not desirable'
Seraja offers new app for citizen journalists
FDI proposals worth Rs 992 cr cleared
UK prospects waning for Indian nurses
Adecco, Tata Institute sign pact
MedRP launches Kochi operations
Be globally competitive, students urged
OECD urges India to ease labour laws
IOB unveils new tax saving deposit scheme
Output shortfall, rising prices may hit chilli exports
Imported wheat arrivals top 12 lakh tonnes
Edible oil imports down in August
Cotton textile exports cross target
Tourism award for Somatheeram
Ayurveda manual
Uttaranchal seeks KSINC help to boost tourism
Seminar on ISO certification

The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription
Group Sites: The Hindu | The Hindu ePaper | Business Line | Business Line ePaper | Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |

Copyright 2006, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line